A new migraine drug could be nearing approval; gunshot victims face long-term risks

Friday, December 6, 2019

More phase 3 ubrogepant data published as FDA decision nears

By Jake Remaly

An acute treatment for migraine shows positive results in a phase 3 trial.

Other news:

Gunshot wound victims are at high risk for readmission
Individuals who sustain gunshot wounds have an increased risk for rehospitalization years, and even decades, after their initial injury.

FDA expands use of Toujeo to childhood type 1 diabetes
The new indication includes children as young as 6 years of age.

FDA approves Tula system for recurrent pediatric ear infections
The system can be used in an office setting under local anesthesia.

Higher risk of bipolar disorder, depression, anxiety found with autism
The study supports the importance of early and ongoing surveillance, the researchers said.

You can contact the MDedge Daily Medical News by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.